This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the topline results of the Phase 3 TRuE-AD3 clinical trial of Opzelura (Ruxolitinib Cream) in children with atopic dermatitis.

Ticker(s): INCY

Who's the expert?

Institution: Cincinnati Children’s Hospital

  • Pediatric Dermatologist who specializes in medical and procedural dermatology 
  • Did a year of research studying vascular anomalies at Boston Children’s Hospital during medical school at Tufts University
  • Manages 5 patients with DEB

Interview Goal
To discuss the standard of care and the potential of Opzelura (Ruxolitinib Cream), a topical selective JAK inhibitor for the treatment of mild to moderate atopic dermatitis from Incyte Bio.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.